Leading Israeli Cannabis Company Goes Public
Ryan Allway
October 24th, 2019
App, Exclusive, News, Top Story
Rolling Stone magazine has called Israel a “medical weed wonderland.” Former Israeli Prime Minister Ehud Barack said earlier this year that the “Land of Milk and Honey” is now the “Land of Milk, Honey and Cannabis.” The man that discovered cannabinoids, Dr. Raphael Mechoulam, did so there and continues to conduct his research there to this day. In 1973, Israel legalized medical cannabis.
Indeed, Israel, a diminutive country the size of New Jersey, punches like a heavyweight in the cannabis industry. In January, the Mediterranean country became only the third in the world to allow exports of medical marijuana to countries where it is legal, further cementing its progressive stance and dominant position in the cannabis industry.
Click Here To Receive Isracann’s Investor Presentation
With the ideal climate for industrial scale cultivation and established commerce paths to the vast European markets, it’s no surprise that Israel is a prized market as a center for excellence in agronomy, research, genetics, manufacturing and quality assurance. The favorable backdrop has resulted in advanced corporate development for select companies, such as Isracann Biosciences (CSE: IPOT), which just became a public entity on October 17th, 2019.
Enchanting Old City Jerusalem, Israel
Perfect Environment
Israel is a country that sees 300+ days of sunshine each year. It also has optimal humidity, which safeguards plants from insects and facilitates optimum plant growth without the need for toxins like pesticides. In cannabis cultivation, organic is king. Aiding in growing premium plants is the fact that Israel has high UV rays, which are known to increase yields and improve plant quality.
The sunshine and temperature have other benefits too insomuch that these factors reduce energy consumption, saving on production costs year-round. Utilizing hybrid greenhouse technology and other leading technology today, Isracann is targeting cannabis production costs as low as just 40 cents per gram.
The company is fully funded to develop its 230,000 square-foot property with capacity of 23,500 kilograms (~51,808 pounds) per annum.
“Environment” means more than just the weather. Israel regulators are obviously supportive and hope to have the operation framework in place to begin cannabis exports in early 2020. The country also has robust domestic demand. In fact, Israel is among the highest cannabis use-per-capita in the world at over 27 percent. Recreational cannabis is not legal, but it is decriminalized in Israel with the passage of new laws in April.
Click Here To Receive Isracann’s Investor Presentation
There are currently about 55,000 medical marijuana patients in Israel, with the number expected to rise to 90,000 next year. Isracann intends to fill this underserved market while penetrating European markets via partnerships.
Want Europe? Get Germany First.
The global legal cannabis (recreational and medical) market is estimated to reach $146.6 billion by 2025. As a subset, the European Union medical cannabis market is forecast to be $64 billion by 2028, as demand rises and additional countries enact new cannabis-friendly legislation.
Germany, the biggest economy in the E.U., is the initial export market for Isracann via a MC-GAP/GSP certification. Currently, Germany has no cultivation laws and imports all its cannabis from the only two other countries with legal exports, Canada and the Netherlands. Israel will soon join in that mix and Isracann wants to be a part of it.
Through its strategic distribution partner, Isracann has a practical intermediate multinational trans-shipment entry point accessing Germany, United Kingdom, Poland and Denmark.
Ground Cannabis shaped as the world
Just like in other countries, the negative stigma associated with cannabis is slowly fading, underscored by educating the general population of the potential medicinal benefits as a therapy for traditionally challenging diseases and conditions. Cannabis has a robust therapeutic profile, touted to treat everything from dry skin to anxiety to chronic pain to epileptic seizures.
German health care covered $75 million of cannabis products last year. During 2018, Germany’s four major health insurers, AOK-Bundesverband, Barmer, Techniker and DAK-Gesundheit, received nearly 20,000 applications for reimbursement of cannabis therapies.
Click Here To Receive Isracann’s Investor Presentation
It seems most plausible that the country of 83 million people will continue to see increased demand over the coming years. That goes without mentioning the other 430 million people living in the European Union that one day could have access to legal cannabis.
The race to get those patients as loyal customers is on and you can bet that Isracann is eager to start planting its “Made in Israel Cannabis” flag to get their attention.
For Additional Information, visit the company’s website at www.isracann.com.
Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Xtraction Services provides state-of-the-art, fully-automated, supercritical CO2 extraction machines with on-site staffing at no upfront cost, and a simple volume-based pricing model.
DNA Genetics has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
